Vera Therapeutics, Inc. VERA 深 滬
已收盤 08-15 16:00:00 美东时间
21.54
+0.270
+1.27%
華盛通- 最 高21.915
- 今 開21.45
- 成交量 193.67万股
- 最 低 21.275
- 昨 收 21.27
- 總市值 13.74亿
- 52周最高 51.61
- 市盈率 靜 --
- 換手率 3.04%
- 52周最低 18.53
- 委 比 9.56%
- 總股本 6377.42万
- 歷史最高 51.61
- 量 比 1.30
- 振 幅 3.01%
- 歷史最低 5.20
- 每 手 1
- 風險率 9.63%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | DoorDash获上调目标价从230美元升至300美元； 摩根大通上调Shopify目标价从115美元升至179美元
今日重点评级关注：HC Wainwright & Co.：维持FibroGen"买入"评级，目标价从10美元升至43美元；摩根大通：维持Cogent Biosciences"超配"评级，目标价从29美元升至30美元
08-08 09:34
Vera Therapeutics Q2 2025 EPS $(1.20) Misses $(0.83) Estimate, Vera Reported $556.8M In Cash, Cash Equivalents, And Marketable Securities
Vera expects cash position to be sufficient to fund operations through potential approval and us commercial launch of Atacicept anticipated in 2026 and beyond
08-05 19:13
Vera Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results
Vera Therapeutics announced positive clinical results from the ORIGIN 3 trial of atacicept for IgA Nephropathy (IgAN), demonstrating a significant reduction in proteinuria and a favorable safety profile. The company plans to submit a Biologics License Application (BLA) for accelerated approval to the U.S. FDA in Q4 2025, with a potential commercial launch in 2026. Vera also initiated the PIONEER trial to evaluate atacicept in broader IgAN populat...
08-05 11:00
Wolfe Research Downgrades Vera Therapeutics to Peer Perform
Wolfe Research analyst Andy Chen downgrades Vera Therapeutics (NASDAQ:VERA) from Outperform to Peer Perform.
08-04 19:25
Veranda Learning Solutions Announces EGM for 2025-26
Veranda Learning Solutions Ltd. ( ($IN:VERANDA) ) has shared an update. Veranda...
08-04 00:12
Stanley Black & Decker Reports 2Q 2025 Results
DEWALT Delivered Topline Growth Due to Relatively Resilient Professional Demand Continued Cost Discipline and Price Measures Partially Mitigated External Pressures and Helped Protect Profit...
07-29 18:00
康恩贝培哚普利氨氯地平片获批，视同通过仿制药一致性评价
近日，康恩贝股份全资子公司杭州康恩贝收到国家药监局核准签发的培哚普利氨氯地平片（Ⅲ）《药品注册证书》，以化学药品4类获批，视同通过仿制药一致性评价。 培哚普利氨...
07-29 08:57
Veralto Reports Second Quarter 2025 Results
WALTHAM, Mass., July 28, 2025 /PRNewswire/ -- Veralto (NYSE: VLTO) (the "Company"), a global leader in essential water and product quality solutions dedicated to Safeguarding the World's Mos...
07-29 04:30
Berkshire Hills Reports Strong Earnings Growth
Second Quarter 2025 GAAP EPS $0.66; Operating EPS $0.69 15% increase in operating EPS linked quarter; 25% increase year-over-year 3% increase in operating revenue linked quarter, 2% decrease...
07-24 19:30
Catalyst Bancorp, Inc. Announces 2025 Second Quarter Results
OPELOUSAS, La., July 24, 2025 /PRNewswire/ -- Catalyst Bancorp, Inc. (Nasdaq: "CLST") (the "Company"), the parent company for Catalyst Bank (the "Bank") (www.catalystbank.com), reported net ...
07-24 19:00
